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Abstract
Aberrant Ras activity is a hallmark of diverse cancers and developmental diseases. Unfortunately, conventional efforts to
develop effective small molecule Ras inhibitors have met with limited success. We have developed a novel multi-level
computational approach to discover potential inhibitors of previously uncharacterized allosteric sites. Our approach couples
bioinformatics analysis, advanced molecular simulations, ensemble docking and initial experimental testing of potential
inhibitors. Molecular dynamics simulation highlighted conserved allosteric coupling of the nucleotide-binding switch region
with distal regions, including loop 7 and helix 5. Bioinformatics methods identified novel transient small molecule binding
pockets close to these regions and in the vicinity of the conformationally responsive switch region. Candidate binders for
these pockets were selected through ensemble docking of ZINC and NCI compound libraries. Finally, cell-based assays
confirmed our hypothesis that the chosen binders can inhibit the downstream signaling activity of Ras. We thus propose
that the predicted allosteric sites are viable targets for the development and optimization of new drugs.
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Introduction
Ras proteins are key regulators of signaling pathways controlling
normal cell proliferation and malignant transformation. Signal
propagation through Ras is mediated by a regulated GTPase cycle
that leads to active and inactive conformations, which differ
significantly in their affinity for downstream effectors. Somatic
point mutations that perturb the fidelity of this cycle can lead to
constitutively active oncogenic Ras [1]. Such mutants are found in
about a third of all human tumors where they contribute to the
deregulation of cell growth, tumor invasiveness and new blood
vessel formation [2]. Germline Ras mutations are also frequently
expressed in patients suffering from a group of related develop-
mental disorders, referred to collectively as neuro-cardio-facial-
cutaneous syndrome [3,4,5]. These disorders share a variable
degree of mental retardation, cardiac defects, craniofacial
dysmorphism, and short stature [6]. Therapies that target Ras
proteins and the signaling pathways under their regulations are
thus of major importance for human health.
Considerable effort has been directed towards inhibiting Ras
processing enzymes and major components of Ras signaling
pathways. Inhibitors of farnesyl and palmitoyl transferases [7]
have been investigated for their potential to attenuate C-terminal
lipid modification of Ras required for correct plasma membrane
localization and subsequent signaling. A drawback of such
inhibitors is their poor selectivity as they likely affect many lipid-
modified proteins. Furthermore, the most promising farnesyl-
transferase inhibitors failed to achieve their intended goal of
disrupting Ras membrane-binding [8]. Indeed the most frequently
mutated Ras isoforms in human tumors (K-Ras and N-Ras) were
found to undergo alternative prenylation and remain oncogeni-
cally active [9]. Attempting to inhibit the function of K-Ras and
N-Ras by using a combination of prenylation inhibitors failed
because of the very high toxicity associated with the required
combination therapy [10]. Indeed, it is likely that the lack of
toxicity associated with farnesyltransferase inhibitors in isolation is
due to their inability to inhibit the functions of the endogenous Ras
isoforms essential for normal cell viability. Another approach has
involved inhibitors of the upstream protein kinase regulators and
downstream effectors of Ras, for example, receptor tyrosine kinase
inhibitors and components of the RAF-MAPK pathway [11,12].
However, because Ras proteins are activated by a myriad of
stimuli and utilize a multitude of downstream effectors, a
particular kinase inhibitor will likely impair only a subset of Ras
functions leading to potentially limited therapeutic benefits.
The development of small-molecule inhibitors that directly target
Ras is highly desirable but has proven to be a major challenge.
Notable issues include the limited bioavailability of drugs that target
highly polar active sites, such as the nucleotide-binding site of Ras,
also known as the switch region [13]. Additional selectivity and
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region across small G-proteins and the wider P-loop NTPase
superfamily. Furthermore, Ras signaling involves a tightly regulated
network of multiple positive and negative regulators with a specific
spatiotemporal organization on cellular membranes [2]. It is the
balance of these positive and negative regulators that ultimately
determines the fraction of GTP-bound active and GDP-bound
inactive Ras. Currently it is not clear if normal and aberrant Ras
have distinct plasma-membrane organizations that can lead to
differential accessibility to downstream effectors and/or upstream
exchange factors. These complications may explain, at least in part,
why Ras-binders that have promising anti-cancer activity in pre-
clinical models failed in clinical trials [14].
The development of compounds with selectivity for K-Ras over
H-Ras would be particularly desirable. Silencing of K-Ras by
siRNA [15,16], miRNA [17,18] or antisense K-Ras [19] has been
shown to result in reversal of transformed phenotypes and
suppression of tumorigenicity in human cancer cells. Studies of
the three major H-, K-, and N-Ras isoforms [20] suggest that
differential membrane-organization may underlie the association
of these highly similar proteins with different diseases [1].
Similarly, recent evidence from experimental [21,22] and
computational efforts [23,24] suggests that oncogenic and normal
Ras proteins harbor distinct dynamic properties that may lead to
differences in membrane binding [25]. Of special note are long-
range coupled motions between the conserved N-terminal lobe1
(residues 1–86, which includes the switch region) and the more
variable membrane-interacting lobe2 [23] (Fig. 1). Such dynamic
behaviors are not always captured in crystallographic structures.
For example, while the overall structures of wild-type H-Ras and
the oncogenic variant G12V-H-Ras are very similar, the latter
exhibits enhanced dynamics [26] and is more susceptible to adopt
an active-like conformation [23]. Here we ask if such motional
differences can be exploited to develop new allosteric inhibitors
that selectively target a specific malfunctioning Ras protein.
In subsequent sections we describe the application of an
integrated bioinformatics approach that couples fragment, grid
and ligand based binding-site mapping methods with virtual
screening (VS) of small molecule libraries against an ensemble of
distinct Ras conformers. Four non-nucleotide binding pockets were
identified in available crystal structures and molecular dynamics
simulated conformers. Simulations reveal that three of these distal
pockets have the potential to be allosterically linked to the switch
region. Furthermore, a number of lead compounds predicted to
bind these allosteric sites were tested experimentally and found to
exhibit inhibitory activity in Ras-expressing cancer cells.
Results and Discussion
A structural ensemble scheme to account for
conformational diversity
Conformational transitions are essential for modulating Ras
signaling activity. These transitions have the potential to expose
transient surface pockets and allosteric sites of significance for drug
discovery. Indeed the merit of accounting for receptor flexibility in
ligand design [27,28,29,30,31], especially in the development of
allosteric inhibitors [32,33], is now well recognized. In the current
work, we combine analysis of multiple conformationally distinct
crystallographic structures with molecular dynamics (MD) trajecto-
ry analysis. This ensemble approach differs from earlier virtual
screening studies on single crystallographic structures [34,35] by
accounting for the intrinsicconformational mobility of Rasproteins.
Ras crystal structure representatives were selected based on a
previously developed protocol for the analysis of inter-conformer
relationships in families of protein structures [23,24,36,37].
Principal component analyses (PCA) and RMSD based clustering
of available structures indicate the existence of distinct Ras
conformational groupings (Fig. S1). It has been noted previously
that the PCA based groupings correlate with the nature of the
bound nucleotide or the presence of a mutation in the vicinity of
the nucleotide-binding site [23,24]. Considering these differences
in bound nucleotide and mutation, as well as isoform, seven
representative structures, termed the crystallographic ensemble,
were used for further analysis (Table S1). Additional conformers
were derived from MD simulations performed on the K-Ras (the
most frequently mutated isoform in a wide range of cancers
[38,39]). Conformers from a total of 120 ns multi-copy simulations
performed in the presence of GTP and GDP were subjected to
PCA and RMSD clustering analysis similar to that performed on
the available crystal structures (see Methods). In this manner, eight
representative MD ensemble conformers were appended to the
crystallographic ensemble and used for binding site mapping and
small molecule docking studies described below.
Ensemble binding site mapping
A combination of fragment, grid and ligand based methods was
employed to identify potential small molecule binding sites on our
Figure 1. The N-terminal (cyan) and the C-terminal (pink) lobes of K-Ras (PDB code: 2PMX). The switches 1 (blue) and 2 (red), that form
the nucleotide-binding site, are situated in the N-terminal lobes. GTP (yellow) is shown as sticks.
doi:10.1371/journal.pone.0025711.g001
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aided structure based drug design is to aim for inhibitors that
compete with an enzyme’s cognate substrate [40]. However, in the
current work, we deliberately focused on the identification of
potential allosteric small molecule binding sites that are distal from
the nucleotide-binding site (see Introduction). Taking the union of
identified sites from a combination of different methods increases
our chances of mapping all such sites at the expense of considering
potentially more spurious sites [41].
Fragment based pocket analysis
We first used a fragment based approach (FTMAP) that is based
on the ideas behind screening small organic fragments by NMR
and X-ray crystallography [42]. FTMAP correlates pocket
druggability with their propensity to bind clusters of small organic
compounds. Fig. 2 displays the mapping results across our
ensemble of Ras crystal structures. To further characterize the
location of each hot spot, an ensemble normalized probe
occupancy value was calculated and assigned to each residue of
the catalytic domain (Fig. 3). As expected, high probe occupancy
values were obtained for residues around the nucleotide-binding
site (red in Figs. 2 and 3 and Movie S1), consistent with the
existence of this binding site in all conformers. Three additional
pockets, displaying low and high occupancies, were also identified
(termed p1, p2 and p3 and rendered in pink, green and blue
respectively in Figs. 2 and 3 and Movie S1).
Sites with low probe occupancy values identify regions on the
protein surface where potential interaction sites are exposed only
in a subset of conformations (reflecting the intrinsic dynamic
nature of these binding pockets). This includes pockets p1 and p2
that reside on either side of the highly mobile helix a2. Residues
from a2 and b-strands 1–3 (in lobe1) line p1, whilst p2 lies between
helices a2 and a3 at the interface between the two lobes (see
Table 1). The large relative displacement of a2 between GDP-
and GTP- like conformers effectively modulates the accessibility of
these two pockets. These nucleotide-associated displacements
effectively link the conformations of p1 and p2 to that of the
nucleotide-binding site. Of particular note is Tyr71 that lies at the
center of pocket p1 blocking ligand binding in the crystal
structures of GDP-H-Ras and H-Ras-G12V. During simulations
this residue is observed to reorient so as to no longer block p1
pocket accessibility (Fig. S2).
The most distal non active site pocket, p3, resides in lobe2
approximately 25 A ˚ from the nucleotide-binding site. Residues
from loop 7 and the C-terminal end of helix 5 line this pocket
which has a mostly hydrophobic interior but is surrounded by
polar residues K104, S106, D108 and H166. Pocket p3 can vary in
size in the ensemble, due predominately to small displacements of
loop 7 residues. Indeed loop7 and helix 5 are observed to adopt
distinct conformations in the GTP-, GDP-, and intermediate
ensemble structures. However, pocket p3 is observed in all
ensemble conformers in contrast to pockets p1 and p2 that are
inaccessible in some members of the ensemble. Considering the
dynamic nature of loop 7, a5 and a2 that line pockets p1–3, we
hypothesized that VS with our ensemble of conformers may allow
us to find new ligand poses that would not be observed with any
single crystallographic structure. Finally, we note that the loop 7
Figure 2. Results of ensemble fragment mapping analysis. Sites identified include the nucleotide-binding site (red) and new potential binding
sites p1, p2 and p3 (in pink, green and blue respectively, see also Fig. 3).
doi:10.1371/journal.pone.0025711.g002
Figure 3. Probe binding ‘‘hot-spot’’ residues across the Ras
ensemble conformers highlight the nucleotide-binding site
(red) and new potential binding sites p1, p2 and p3 (in pink,
green and blue respectively, see also Fig. 2).
doi:10.1371/journal.pone.0025711.g003
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motions with the active site [23,24,43].
Grid energy based pocket analysis
In addition to fragment based mapping we employed grid
energy based pocket identification with the AutoLigand package
[44]. AutoLigand searches the exterior surface space of a protein
for contiguous volume envelopes with potentially favorable
interaction energies for small molecules. Applying this method
across the Ras structural ensemble highlighted two of the three
previous FTMAP identified binding sites, p1 and p3 (Table 1). An
additional pocket, here termed p3b was identified immediately
adjacent to pocket p3. Both pockets p3 and its extension p3b share
residues from loop 7 and the C-terminal end of helix a5. However
p3b extends toward loop 5 and p3 toward loop 9 (Fig. 4). Pocket
p3b is rich in charged residues including E162 that provides a
negatively charged site at the bottom of the p3b pocket. Pocket
p3b is significantly smaller and shallower than pockets p1–3 as
highlighted by FTMAP (Table 1 and Fig. 4), which likely
explains why it did not feature in fragment based (described above)
or ligand based (described below) site identification.
Ligand based pocket analysis
As a final step inourcharacterizationof potential bindingsiteswe
performed a blind docking of known small-molecule Ras binding
molecules. The basic premise of this approach is that a ligand
frequently targets a given site if that site offers an energetic or steric
advantage over any other site [45,46]. A library of putative ligands
that were shown to bind to Ras at unknown sites from high
throughput bioassay data were ‘‘blind-docked’’ onto the entire
surface of a single K-Ras crystal structure (see methods). By
counting the number of compounds that target a given site,
weighted bythefrequency with which a given compound targetsthe
site, we found two prominent binding sites (Table 1 and Fig. 4):
one that coincides with pocket p3 (targeted by ,80% of
compounds) and a second novel pocket, p4, behind the flexible
effector binding loop (targeted by ,3% of the compounds). To
ensure that this dramatic preference for pocket p3 is not biased by
the choice of a specific small molecule set, we blind-docked 20 top-
ranking compounds derived from a site-directed VS of the NCI and
ZINC libraries against the entire crystallographic- and MD-
ensembles (to be discussed). We found that these compounds tend
to preferentially bind pocket p3, and to a lesser extent to p4. For
instance, of the top-ranking poses, 12 out of the 14 ZINC
compounds bind to p3 and the other 2 at p4. Similarly, 2 out of
the6NCIcompoundspreferentially targetp3whiletheremaining4
target pocket p4. Overall, it is noteworthy that three distinct
procedures applied to a different set of ligand libraries and fragment
probes highlighted the same potential pockets.
Ensemble virtual screening against the novel binding sites
Compounds from the NCIDS II and Zinc drugs-now subset
were docked against the identified pockets in each of our ensemble
Table 1. Results of pocket identification on the Ras structural ensemble through fragment (FTMAP), grid (AutoLigand) and ligand
(BlindDock) based site identification schemes.
Pocket FTMAP AutoLigand BlindDock Location Mean volume
P1 5–7,39,54–56, 67, 70–75 5,7,39,54–56,70–72,74–75 N.A. b1–3 and a2 112 (78.6)
P2 61–65, 90–99 N.A. N.A. L2, a2a n da3 143.6 (120)
P3 97,101,107–111, 136–140,
161–166
97,101,107–111,137–140,
161–163,165–166
97,101,107–112, 137–
140,159,162, 163,165, 166
L7, L9 and a5 173 (18.7)
P3b N.A. 75–78,104,106–110, 162–166 N.A. L5, L7 and a5 36 (2.1)
P4 N.A. N.A. 24–40, 17, 21, 57 L2, a1a n db2 139.9 (57.6)
Location specifies surrounding 2u structure elements. Mean pocket volume and standard deviation across the ensemble is calculated with the Povme program [63] (see
methods).
doi:10.1371/journal.pone.0025711.t001
Figure 4. Potential small-molecule binding sites identified on the Ras structural ensemble. The residues lining each pocket are listed in
Table 1. The color scheme for each pocket is as in the Figure 2, with p3b (orange) and p4 (yellow) additions.
doi:10.1371/journal.pone.0025711.g004
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re-scored compounds ranked as top 20 using eight different
scoring functions (see Methods). A total of 195 and 256 top scoring
unique compounds were obtained from the screening against the
crystallographic and MD ensemble, respectively. A total of 56 of
the top-scoring compounds (ranked within the top 20) were able to
target the same site in both the crystallographic- and MD-
ensembles. The MD-ensemble yielded 26 additional compounds
not detected in the screening against the crystallographic-
ensemble. Furthermore, some compounds that scored poorly in
the crystallographic-ensemble scored well in the MD-ensemble.
Such an improvement of the rankings and the appearance of 26
additional compounds as top scorers in the MD-ensemble is
largely due to conformers that lie in-between the major GTP- and
GDP-clusters (Fig. S3). This result highlights the benefit of
utilizing the MD-based relaxed complex scheme in addition to the
traditional approach of relying on one or a few average X-ray
structures [29,49]. It is important to also note that the
crystallographic ensemble is dominated by H-Ras structures (both
wild-type and mutant), whereas the MD-ensemble contains only
K-Ras structures. It is possible that some of the 26 ligands that
appear only in the MD-ensemble may be K-Ras-selective. For
subsequent analysis, we focused on the 56 compounds that scored
high in both the crystallographic- and MD-ensembles as well as
the 26 compounds that are unique to the MD-ensemble. After
Lipinski-filtering and visual inspection 19 ligands were selected as
promising leads and submitted for experimental testing (Table 2).
Experimental Testing
It is well known that Ras can activate the Raf/Mek/Erk signaling
pathway. In order to select an appropriate cell line to evaluate the
inhibitory properties of the candidate compounds in vitro,w e
determined basal Ras and ERK1/2 activity in several glioblastoma
cell lines via Ras pull down assays and Western blot analysis,
respectively. Results for four well characterized glioblastoma cell
lines are shown in Fig. 5A. Among the lines examined, the U251
cells [50] were found to have the highest level of basal GTP bound
Ras and this was associated with high basal downstream ERK1/2
phosphorylation (Fig. 5A). We employed this cell line to test the
ability of the candidate inhibitor compounds to block the Ras-ERK
pathway. We first determined the effect of each of four lead
candidate compounds on ERK1/2 activation. Compounds were
initiallytested ata concentrationof10 mMandcellsweretreatedfor
24 hrs to allow adequate time to achieve decreases in steady state
Ras and ERK activity levels. As shown in Fig. 5B, immunoblot
analysis demonstrated that compounds 662796, 643000 and
117028 inhibited ERK1/2 phosphorylation in U251 glioblastoma
cells. ERK1/2 phosphorylation levels from four separate experi-
ments were quantitated and compounds 662796, 643000 and
117028 shown to elicit significant (50 to 75%) decreases in ERK1/2
activation. We next examined the ability of these compounds to
decrease Ras activity in U251 cells (Fig. 5C). Ras pull down assays
were performed to assess GTP bound (active) Ras. Two of the three
compounds that suppressed ERK1/2 phosphorylation (643000 and
117028) also inhibited Ras activation in U251 cells. These data
suggest that the ability of compounds 643000 and 117028 to
decrease ERK1/2 phosphorylation derives from inhibition of Ras
activity rather than nonspecific inhibitory effects on the ERK
activation cascade downstream of Ras. We subsequently examined
the dose dependence of Ras inhibition by compounds 643000 and
117028. Both compounds decreased basal Ras activity in a dose-
dependent manner (Fig. 5C). For compound 64300, the half
maximal inhibitory concentration appeared to be approximately
10–30 mM and nearly complete inhibition was achieved. For
compound 117028, the maximal decrease achieved was approxi-
mately 40%. This may reflect the fact that there is a presence of
Table 2. Ensemble docking hits selected for experimental testing.
Compund ID Ligand dataset Potential Pocket nOHNH nON LogP MW
16195481 PubChem Bioassay p3 4 8 1.626 420.52
5446021 PubChem Bioassay p3 3 7 2.567 397.46
5446018 PubChem Bioassay p3 3 7 1.882 397.46
5295758 PubChem Bioassay p3 1 6 3.57 415.56
4121863 PubChem Bioassay p3 3 5 4.83 392.53
3227807 PubChem Bioassay p3 1 8 3.737 447.52
12971189 Zinc drugs-now subset p3 3 6 0.515 228.26
16958504 Zinc drugs-now subset p3 4 9 23.901 305.32
17047255 Zinc drugs-now subset p3 7 6 20.524 279.33
19166944 Zinc drugs-now subset p3 1 5 21.04 312.37
24983237 Zinc drugs-now subset p3 4 9 24.469 335.37
6682086 Zinc drugs-now subset p3 3 5 20.247 300.38
6691859 Zinc drugs-now subset p3 7 6 23.477 185.26
13616 NCIDS II p3 2 4 4.317 327.46
23895 NCIDS II p3 2 4 2.857 221.25
36818 NCIDS II p3 2 8 1.602 374.48
99660 NCIDS II p3 1 6 1.105 339.48
117028 NCIDS II p3 1 4 4.06 398.30
121182 NCIDS II p3 6 9 22.303 266.26
nOHNH, number of hydrogen bond donors; nON, number of hydrogen bond acceptors; MW, molecular weight.
doi:10.1371/journal.pone.0025711.t002
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glioblastoma cell line. Nonetheless the ability of these non-
optimized, computationally selected Ras inhibitory compounds to
decrease the amount of constitutively active Ras, and its
downstream target ERK, in this glioblastoma cell line suggests that
this strategy holds considerable promise for limiting aberrant cancer
cell growth mediated through this pathway.
A proposed mechanism of action of the predicted
ligands
The most prominent putative ligand binding site, p3, as well as
its extension p3b, are located on lobe 2 near the C-terminus that
leads to the membrane-interacting hypervariable region. Given
our earlier MD and cell-biological studies that found that
membrane-binding by the full length H-Ras [21,22,51] is
allosterically modulated by the bound nucleotide, it is tempting
to speculate that ligands targeting the predicted allosteric sites may
interfere with Ras’ attachment to the plasma membrane. It is also
possible, however, that ligands that target these sites could
allosterically modulate the conformation of the canonical switch
region. This is consistent with the observed long-range coupled
motions of loop 7 with the active site [23,24,43,52]. Furthermore,
a study combining crystallography, paramagnetic relaxation
enhancement and calorimetry found that divalent ion-cyclen
binding at a site equivalent to p3 allosterically stabilizes an
effector-loop conformation with a weak potential for effector
binding [53,54]. Similarly, the current ligands may selectively
stabilize GDP-like or transient structures and thereby decrease the
pool of GTP-bound Ras through a population-shift mechanism
[55]. Although further investigations are required to determine if
the predicted ligands bind at the predicted sites, it is encouraging
that they reduce ERK phosphorylation (activation) in U251 cells
Figure 5. Experimental testing of candidate inhibitors. (A,top). The U138, U251, U373 and U343 glioblastoma cells were serum-starved for
48 hours and active Ras was precipitated with GST-fused Ras-binding domain of Raf-1 (Raf-1 RBD)-agarose beads and probed with anti-Ras antibody.
(A,bottom) Lysates were immunoblotted for P-ERK1/2 or total ERK1/2. Data were quantitated and averaged from 4 independent experiments and
presented as means 6 SEM of the ratio of active Ras to total Ras (top) or the ratio of phosphorylated ERK1/2 to total ERK1/2 (bottom).
*P,0.05 for
U251 vs U138, U373 and U343, one-way ANOVA. (B) Serum-starved U251 glioblastoma cells were treated with either vehicle (DMSO) control or 10 mM
of the indicated compound for 24 hours. Cell lysates were immunoblotted for P-ERK1/2 or total ERK1/2. Immunoblots are representative of four
independent experiments which were quantitated and shown graphically as means 6 SEM;
*P,0.05 vs. vehicle control, one-way ANOVA. (C) Cells
(U251) were serum starved and subsequently treated with compound 643000 (left) or compound 117028 (right) at the indicated concentrations for
24 hours. Ras activity was assessed using the pull down assay. Immunoblots are representative of four independent experiments, which were
quantitated and plotted as percent of vehicle control. Values are means 6 SEM;
*P,0.05 vs. vehicle control for compound 643000;
**P,0.01 vs.
vehicle control for compound 117028.
doi:10.1371/journal.pone.0025711.g005
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Assuming that the compounds bind to Ras as predicted, we
propose that they act by allosterically modulating membrane
binding or, more likely, the catalytic site architecture.
Encouragingly, the micromolar anti-Ras activities observed in
our initial experiments suggest that the predicted ligands may
indeed serve as viable starting points for the lead generation
against deregulated Ras signaling. Of special interest in terms of
specificity are allosteric ligands targeting pocket p3 and p3b near
the C-terminus and distal from the active site. The close proximity
of these binding sites, and the fact that some compounds bind
across multiple sites, provide an opportunity for linked-fragment
drug design [56]. The bridging compounds can be used as
scaffolds to discover new drugs with enhanced affinity and
specificity. Obviously, the ligands identified in this work might
not have high-affinity (tens of mM was required in our cell-based
assays), or the required level of selectivity to be effective inhibitors.
However, they can serve as crucial starting points for future
development of new therapeutics against deregulated Ras
signaling for which no selective inhibitors are available.
A major goal of the current work was to identify and validate
novel drug binding sites on the Ras catalytic domain. Using a
battery of computational techniques, that incorporate global
conformational fluctuations into the hit identification process,
we have shown that there are at least four potential allosteric
pockets on the Ras catalytic domain. One of these novel sites
near the C-terminus, termed p3, is of particular interest for
inhibitor development. It is the most frequently targeted pocket
both during our blind docking and VS exercises. That this
pocket is involved in correlated motions with the active site [43]
suggests that ligand binding at this pocket may allosterically
modulate the active site architecture, as shown in other proteins
[57,58,59]. This is consistent with the report that divalent ion-
cyclen binding at p3 stabilizes a conformation that has weak
effector-binding potential [54]. Thus, we propose that pocket p3
is a viable target against which leads can be generated to serve as
starting points for the development and optimization of new
drugs.
Methods
Structural ensemble generation
Available Ras crystallographic structures and MD simulation
snapshots (see below) were analyzed using the Bio3D package [36].
Details of this procedure have been described previously [23,24],
briefly, structural superposition was performed on the invariant
‘‘core’’ as defined by Grant et al. [36]. Next, the Cartesian
coordinates of equivalent Ca atoms were used to define the
elements of a covariance matrix. The covariance matrix was then
diagonalized to derive principal components with their associated
variances. The crystallographic and MD conformers were
projected into the sub-space defined by PC1-3 where the
maximum variation of the conformational distribution was
observed (see [23,24] for further details). Structures then
underwent average-linkage hierarchical clustering according to
the pairwise distances obtained from their projection onto the first
three principal components obtained from analysis of available
crystal structures. Clustering based on pairwise Ca atom RMSD
yielded similar major clusters. Inspection of the resulting
dendogram was used to partition structures into seven to eight
dominant groups (ranked according to their populations). The
closest structure to the average structure from each cluster, in
terms of RMSD, was chosen as a representative for further binding
site mapping and virtual screening analysis.
Identification of novel binding sites
We used the FTMap method of Brenke and co-workers to
highlight regions on the Ras catalytic domain surface that have the
potential to bind the highest number of small molecular probes
[42]. Both crystal structures and each cluster representative from
MD were subject to fragment mapping. Hot-spot residues (those
that comprise prominent fragment binding sites) across all
structures were analyzed with the Bio3D package. A residue was
assumed to be in contact with a probe molecule if any two heavy
atoms from the probe and residue were within 5.0 A ˚.
To further characterize novel binding sites we used AutoLigand
from the AutoDockTools (ADT) package [44]. AutoLigand
predicts possible ligand-binding sites by searching for a contiguous
envelope with the specified volume of 70 favorable energy points
that represent potential atomic centers for ligand atoms. We
applied AutoLigand to scan each conformer in the structural
ensemble. High affinity binding pockets in each of the Ras
conformers were identified and the common residues lining those
sites were determined using Bio3D. As a positive control,
AutoLigand and FTMAP both successfully identified the nucle-
otide-binding site in all ensemble conformers.
An additional ‘‘blind docking’’ ligand based search with known
Ras binders in public databases was used to determine if there are
sites on Ras that are frequently visited by a library of small
molecule compounds. It was shown that such blind docking
procedures correctly identify binding sites in 80% of cases but fail
to discriminate between true ligands and decoys [60]. We used
AutoDock 4.2 [61] to ‘‘blind dock’’ a library of 267 putative
ligands from the PubChem Bioassy database. These compounds
were shown to bind to Ras at unknown sites. The PubChem
Bioassy database has potential Ras inhibitors comprising 267
compounds as determined by a high throughput fluorescent-GTP
binding assay (AID database accession code: 759). Compounds
inducing at least 20% reduction in fluorescence relative to the
ligand-free control were termed potential inhibitors in the high
throughput assay. For our VS study, the ligands were prepared
with ADT by adding polar hydrogen atoms and calculating the
Gasteiger charges and torsions.
AutoDock 4.2 was used to dock the ligands onto the entire
surface of the K-Ras crystal structure (PDB code 3GFT) with a
grid dimension large enough to cover the entire protein
(14361496155 A ˚, with 0.375 A ˚ grid spacing). The bound GTP-
analogue phosphoaminophosphonic acid-guanylate ester (GNP)
was kept to exclude ligands that may target the catalytic site. A
population size of 400, a 2 A ˚ cutoff for clustering, 1.5610
8 energy
evaluations and 256 hybrid Lamarckian genetic algorithm runs
were used. The predicted poses were analyzed in terms of their
potential to form hydrogen bonds and van der Waals contacts with
the protein. Hydrogen bonds were defined by a donor-acceptor
distance of less than 3.5 A ˚ and a donor-hydrogen-acceptor angle
between 150u and 180u. Van der Waals contacts were defined by a
carbon-carbon distance cutoff of 5.0 A ˚. The relative importance of
target-sites was determined by ranking the docked compounds
according to their empirical inhibition constant after eliminating
compounds that did not consistently bind at the same site and
those violating Lipinski’s rule [62]. Pocket volumes were calculated
with Povme (POcketVolumeMEasurer) program [63] by first
aligning all ensemble conformers.
Molecular dynamics simulation
Simulations of K-Ras were carried out with bound Mg
2+GTP
and Mg
2+GDP, both modeled from a high-resolution crystal
structure of K-Ras (PDB code 2PMX). Protonation states for all
titratable residues were determined using PDB2PQR [64]. The
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addition of missing hydrogen atoms. The systems were neutralized
by addition of counter ions at pH 7 and solvated with TIP3P
waters with the buffering distance of 10 A ˚. All simulations were
performed with the AMBER 10 package [65] and the ff99SB force
field [66] and previously developed parameters for guanine
nucleotides [67].
Energy minimization was carried out with decreasing con-
straints on the heavy atom positions, followed by constant volume
heating to 300 K for ,10 ps, and a 200ps constant temperature
and constant pressure (1 atm) equilibration. The production phase
involved multi-copy unrestrained runs for enhanced sampling and
improved statistics. Three independent 20 ns production runs with
different initial velocities were carried out on each system resulting
in a cumulative simulation time of 120 ns. The integration time
step was 2 fs with bonds involving hydrogen atoms restrained by
SHAKE [68]. Short-range non-bonded interactions were truncat-
ed at 10 A ˚ while long-range electrostatic interactions were
evaluated with the Particle-Mesh Ewald method [69]. All
simulation analysis was performed with the Bio3D package.
Virtual screening
Compounds in the NCIDS II and ZINC drugs-now subset
satisfying a Tanimoto score threshold of 60% were docked into
each of the seven and eight representative conformers of the
crystallographic- and MD-ensembles, respectively. Each protein
conformer was first prepared with the Protein Preparation Wizard
of the Schrodinger program suite (Fig. S4). Bond orders were
assigned, and hydrogen bond networks, rotating hydroxyl and
thiol hydrogens were optimized. A grid enclosing each binding site
of interest was generated using Receptor Grid Generation.
Each compound was prepared using Ligprep of Schrodinger
using the OPLS_2005 force field at pH 7.0+22.0 with ionization
states generated by Epik 1.6. To enhance ligand diversity, for each
ligand up to 32 stereoisomers and 8 low energy ring conformations
were generated, resulting in a total of 5,267 and 39,490 3D
structures for NCIDSII and ZINC, respectively. Then triple steps
virtual screenings, encompassing high throughput virtual screen-
ing, standard precision, and extra precision were performed using
Glide [47,48].
Re-scoring
Each docked pose was re-scored with Accelrys Discovery Studio
using PLP(1 and 2) [70], Jain [71], PMF [72], PMF04 [73] and
Ludi (1, 2, and 3) [74,75,76] scoring functions. Although absolute
scores given by the different scoring methods cannot be compared,
the relative rankings of each compound with the different scoring
methods provide useful information. Thus, compounds ranked as
top 20 with each scoring function were combined to build a new
library for each binding site. Visual analysis and filtering for drug-
likeness by Lipinski’s rule of fives [62,77] (no more than five
hydrogen bond donors, 10 hydrogen bond acceptors, low
molecular weight not greater than 500 g/mol, and a logP not
greater than 5), was applied to further reduce the number of
compounds suggested for experimental testing.
ERK1/2 Phosphorylation Assay
Glioblastoma cells were serum-starved for 24 hours in DMEM
containing 0.1% BSA and subsequently treated or not for
24 hours with compounds obtained from the NCIDS II and
ZINC small molecule database. Cells were washed and lysed in
buffer containing 50 mM Tris HCL (pH 7.4), 100 mM NaCl,
5 mM MgCl2, 0.1% Triton X100, 10% glycerol, 1 mM
phenylmethylsulfonylfluoride, 1 mM DTT, 0.1 mM sodium
orthovanadate, 10 mg/mL leupeptin, and 10 mg/mL aprotinin.
Lysates were clarified by centrifugation and protein content was
measured. Cell lysates were solubilized by boiling for 10 minutes
in Leammli buffer. Proteins were resolved by SDS-PAGE analysis
and membranes were probed with an anti-phospho-ERK1/2
antibody (Cell Signaling). Total ERK1/2 was determined by
immunoblotting with anti-ERK1/2 polyclonal antibody (Cell
Signaling). Proteins were visualized using enhanced chemilumi-
nescence and quantitated using gel documentation software (Alpha
Innotech Corp., San Leandro, CA).
Ras Pull-Down Assay
Ras activation assays were performed following the affinity
precipitation protocol provided by the manufacturer (RAs pull-
down assay kit: Upstate Biotechnology lake Placid, NY). Briefly,
lysates were incubated with Raf-1 RBD for 45 min at 4uC and
then centrifuged to pellet the agarose beads. Agarose beads were
washed, and pellets were resuspended in 26 Laemmli sample
buffer and boiled for 5 min. The supernatant was collected and
cellular proteins were resolved by SDS-PAGE and analyzed by
immunoblotting with an anti-Ras antibody (Cell Signaling).
Statistical Analysis
Statistical analysis was determined using ANOVA followed by
the Tukey multicomparison test. A value of P,0.05 was considered
significant.
Supporting Information
Figure S1 Heat map clustering of Ras structures in the
PC1 to PC3 planes. Structure labels are colored by nucleotide
state (red for GTP and green for GDP). Major conformational
groupings are indicated by the orange labels and corresponding
marginal dendrograms (see text for details).
(TIF)
Figure S2 Pocket p1 dynamics. Residues lining P1 (see
Table 1) are shown in red surface. Tyr71 (magenta) re-
orients to enable access to P1. Probability density of Chi1 side
chain dihedral angles of Tyr 71 shows distinct orientations.
(TIF)
Figure S3 Projection of representative conformers (red)
of K-Ras MD ensemble (blue) on the first two dominant
principal components obtained from the analysis of
crystallographic ensemble. MD conformers lie in between
two major crystal clusters (gray) associated with GTP-bound (PC1:
27 to 0) and GDP-bound (PC1: 15 to 20). The representative
conformers were identified based on RMSD and PCA based
clustering, see text for details.
(TIF)
Figure S4 A multi-level computational approach for the
identification of small molecules that bind to novel
allosteric sites on Ras. MD, molecular dynamics; NCIDS
II, National Cancer Institute diversity set II; HTVS, high
throughput virtual screening; SP, standard precision;
XP, extra precision.
(TIF)
Table S1 Representative structure obtained from ana-
lyzing the Ras crystallographic ensemble.
(DOC)
Movie S1 Ensemble fragment mapping results highlight
three non-nucleotide binding sites. Representative Ras
crystal structure conformers (gray protein cartoon) are shown
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representation) and new potential binding sites p1, p2 and p3 (in
pink, green and blue molecular surface representations respec-
tively). Also shown is an average Ras conformer where relative
chain thickness and color scale (red: high, gray: low) represent
residue wise probe occupancy values (see text for details).
(MP4)
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